Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Renal Cell 32Leukemia 26Melanoma 25Kidney Neoplasms 25Leukemia, Myeloid, Chronic-Phase 22Multiple Myeloma 17Lymphoma 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Neoplasms, Plasma Cell 13Lymphoma, Follicular 12Pancreatic Neoplasms 9Lymphoma, Mantle-Cell 8Leukemia, Lymphocytic, Chronic, B-Cell 8Waldenstrom Macroglobulinemia 7Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Large-Cell, Immunoblastic 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Myeloid, Acute 7Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Accelerated Phase 6Carcinoma, Hepatocellular 6Colorectal Neoplasms 5Urinary Bladder Neoplasms 4Recurrence 4Rectal Neoplasms 4Lung Neoplasms 4Immunoglobulin Light-chain Amyloidosis 4

Interventions

Surveys and Questionnaires 1Sirolimus 1Lymph Node Excision 1Interferon-alpha 1Imiquimod 1Acupuncture Therapy 13-ingenyl angelate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Facies × Interferon-alpha × Clear all
NCT00581425 2013-01-25

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

The University of Texas Health Science Center, Houston

Phase 4 Completed
49 enrolled
Dermatologic

Carcinoma, Basal Cell, Facies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡